A failure in any of these programs could lead to a substantial decrease in investor confidence and stock value. Moreover, as a clinical-stage company without approved products, Fate Therapeutics ...

After hours: January 31 at 6:43:48 PM EST ...

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...